Dasatinib 化学構造
分子量: 488.01

品質と確認

製品表彰状(57)

カスタマーレビュー(10)

Quality Control & MSDS

製品情報

  • Compare Src Inhibitors
    Src阻害剤を比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

情報 Dasatinib は、野生型ablとSrcのためのSrc/abl阻害剤で、IC50 がそれぞれ 0.6 nM と 0.8 nMです。
目標 Abl Src c-Kit (WT)/c-Kit (D816V)
IC50

0.6 nM

0.8 nM [1]

79 nM/37 nM [2]
In vitro試験 Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity Description
M07ep210 NVTMRlMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfpVII4OiCq NFXYfldFVVOR NIHDNWVKSzVyPUCuNFAxODdizszN
K562 MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu3NkBp NF3YZ4hFVVOR MlPoTWM2OD1yLkCwNUDPxE1?
M07e MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zKSFczKGh? NFizeHhFVVOR M3[3WmlEPTB;MD6wNFEzKM7:TR?=
ALL3 MWPDfZRwfG:6aXOgRZN{[Xl? MlrBNE4y|ryP NXW2XoRGPzJiaB?= MVrEUXNQ M{HiU2lEPTB;MD6wNFA1KM7:TR?=
CML NYPYbW1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXeyNEBucW5? MYXEUXNQ NEKxOo1KSzVyPUCuNFAyKM7:TR?=
BA/F3 NW\yUlB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfyU3JKPzJiaB?= Ml35SG1UVw>? M1jS[2lEPTB;Nj61PFkh|ryP
BA/F3 NFvj[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIflWnc4OiCq MmLZSG1UVw>? MXTJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?=
BA/F3 M3HMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjRTXY4OiCq MlPUSG1UVw>? M1TocWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1?
BA/F3 NUe5O2pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHMT3pYPzJiaB?= NH;udGpFVVOR M{W2Rmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygWFMyPUlibYX0ZY51KHerdHigTWM2OCCxZjCxMlcyPM7:TR?=
BA/F3 NFHrT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDub5hUPzJiaB?= MoK4SG1UVw>? M1\0T2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6|ryP
BA/F3 M{HueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTKXoV7PzJiaB?= MVTEUXNQ MoHSTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN|LPxE1?
BA/F3 M3TIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXKdo05PzJiaB?= NYjJ[oF1TE2VTx?= M372S2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy|ryP
BA/F3 NUHTTGxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF2wfXo4OiCq M1i5TWROW09? NFnoeHFKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCTMkWyTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA5|ryP
BA/F3 M1PPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zMdlczKGh? MULEUXNQ MWrJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOzV7VjDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxN:69VQ>?
BA/F3 NVKzS2NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq3NkBp NYHZcZZkTE2VTx?= M{nUXmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO
BA/F3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvjO|IhcA>? NXr5TIU4TE2VTx?= NH3PfZFKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCC\MkWzTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAzO87:TR?=
BA/F3 MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHOydYI4OiCq NH;q[oFFVVOR NGnHb5BKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>?
BA/F3 M1rveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVO3NkBp NIXzTo1FVVOR NIK0eZhKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2=
T cell M3XQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXi3NkBp MWLEUXNQ MkXOTY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0>
WiDr MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HiflczKGh? NXKwTHRVTE2VTx?= NUfxbG5rUUN3ME2wMlA2OiEQvF2=
PC3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjCO|IhcA>? Mln2SG1UVw>? M335OGlEPTB;MD6wNFk1KM7:TR?=
MDA-MB-231 MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzZO|IhcA>? NEPUOHdFVVOR M1;pRWlEPTB;MD6wNVIh|ryP
Hs578T MYLDfZRwfG:6aXOgRZN{[Xl? NV;ROYJbPzJiaB?= Mli2SG1UVw>? NEnKeFVIUTVyPUCuNFMh|ryP
HMEC MlHTR5l1d3SxeHnjJGF{e2G7 MW[3NkBp NWK0TJBZTE2VTx?= M120b2dKPTB;MT64JO69VQ>?
DU145 NHfQRoNEgXSxdH;4bYMhSXO|YYm= MlnBO|IhcA>? MlrQSG1UVw>? MVvHTVUxRTBwMU[g{txO
U251 Mk\RR5l1d3SxeHnjJGF{e2G7 NWXETmpXPzJiaB?= MVPEUXNQ M4fXe2dKPTB;Mj64NUDPxE1?
NCI60 MkPrR5l1d3SxeHnjJGF{e2G7 M1HYdlczKGh? NFPtPJdFVVOR NXXSTmxET0l3ME21Mlch|ryP
MALME-3M MVfDfZRwfG:6aXOgRZN{[Xl? M4LCR|czKGh? NXnBRWVoTE2VTx?= Ml;TS2k2OD14Lk[xJO69VQ>?
KM12 NWiwSXhCS3m2b4TvfIlkKEG|c3H5 MVi3NkBp MlTUSG1UVw>? M3TNUGdKPTB;Nz60OEDPxE1?
SW620 NULNN4x[S3m2b4TvfIlkKEG|c3H5 M2n0R|czKGh? M1vVXGROW09? M4OyfWdKPTB;OD60N{DPxE1?
RXF 393NL MV7DfZRwfG:6aXOgRZN{[Xl? NUiyPJlxPCCmYYnz MYfEUXNQ MVLJR|UxRTBwMEKxO{DPxE1?
LXFA 983L MYrDfZRwfG:6aXOgRZN{[Xl? NXPoUHRkPCCmYYnz NFLtcY1FVVOR MWjJR|UxRTBwMEW2OUDPxE1?
PRXF DU145 NFHpV3JEgXSxdH;4bYMhSXO|YYm= MoH6OEBl[Xm| NVXUVZlDTE2VTx?= M{P1VWlEPTB;MD6wOlI{KM7:TR?=
PAXF 1657L M1nrcmN6fG:2b4jpZ{BCe3OjeR?= MX:0JIRigXN? MnLtSG1UVw>? M3XiN2lEPTB;MD6xNlEh|ryP
CXF 1103L NEHuOHJEgXSxdH;4bYMhSXO|YYm= MWC0JIRigXN? NXK4VGd{TE2VTx?= NVm4b2V1UUN3ME20MlM3KM7:TR?=
GXF251L NEC0RXFEgXSxdH;4bYMhSXO|YYm= MorEOEBl[Xm| NIK3S|BFVVOR MVjJR|UxRTJwMkWg{txO
NCI-H23 MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjFdnJVPzJiaB?= NH7Xc|JFVVOR MVTJR|UxRTJwMkeg{txO
HCT116 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDiPJRVPzJiaB?= NXjxV5Y4TE2VTx?= MonETWM2OD1{LkOg{txO
MCF7 NYr4foZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HyZlczKGh? NXjqXWRRTE2VTx?= NYf4N3M4UUN3ME2yMlU4KM7:TR?=
NCI-H460 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF2yO4I4OiCq MmexSG1UVw>? MYPJR|UxRThwOUmg{txO
DLD1 M1[wVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{KzSFczKGh? NXLZ[I1STE2VTx?= NGnueWZKSzVyPUSuOkDPxE1?
NCI-H661 NIG2NW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i3NFczKGh? MkHZSG1UVw>? NFO0eHZKSzVyPUeuPEDPxE1?
A549 MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUm3NkBp NWjIZYN1TE2VTx?= MUHJR|UxRThwMjFOwG0>
U937 M4nE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfJbFg4OiCq NVjzWmNITE2VTx?= M2P3PWlEPTB;MUKuNkDPxE1?
HEK293 M2i1WWZ2dmO2aX;uJGF{e2G7 M2LyTFExyqEQvF2= M4f3NWROW09? NYDaOVNSUW6mdXPld{BjcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIZ2dGxvbHXu[5RpKEircz30ZYdo\WRiTYn0NUBscW6jc3Wg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNkROwG0>
HUVEC MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i3XFAvOTYEoN88US=> M{TGSFczKGh? NUn2dWp6TE2VTx?= NIf6fmhKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0>
HUVEC MVrGeY5kfGmxbjDBd5NigQ>? M3T6TVE2yqEQvF2= M2HFW|czKGh? MXvEUXNQ MkTBTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iCwZYT3c5JsKG[xcn3heIlwdiCjdDCxMlghfG9iMUWgeW0>
Plasmodium falciparum NI[zT3JHfW6ldHnvckBCe3OjeR?= M12z[|ExyqEQvF2= M37tbFE2KG2rbh?= M1iwe2ROW09? M2TE[mlvcGmkaYTzJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCycn;sbYZmemG2aX;uJIJ6KGmwaHnibZRqdmdidHjlJGZ2dmO2aX;uJI9nKFCoQ1TQT|EheHKxdHXpckB4cXSqIFnDOVAhd2ZiMT6xO:69VQ>?
PC3 NUPqNYEyTnWwY4Tpc44hSXO|YYm= M{\PbFAvOSEQvF2= NH\tbm02KGh? M2TXTmROW09? MmH5TY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P
DU145 NXjjXlRUTnWwY4Tpc44hSXO|YYm= NY\FelVQOC5zIN88US=> NF\kS|g2KGh? M3r0[GROW09? M1X5SWlvcGmkaYTzJIh2dWGwIFTVNVQ2KGOnbHygZYRp\XOrb36gZZQhOTByIH7N
PC3 NV;oWGFNU2mwYYPlJGF{e2G7 M2f1N|AvOSEQvF2= M1PDVVUhcA>? MoH4SG1UVw>? MlPVTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?=
DU145 M4HaZWtqdmG|ZTDBd5NigQ>? M1mwOVAvOSEQvF2= MV[1JIg> MUTEUXNQ MWPJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2=
PC3 MYHLbY5ie2ViQYPzZZk> NGfxOosxNjFizszN NU\Ub2x4PSCq NH6zU29FVVOR MWfJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0>
DU145 MoGyT4lv[XOnIFHzd4F6 NI\qd4ExNjFizszN MlvXOUBp NFrlSm5FVVOR NVPuNIZKUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2=
Huh7 NYi2b4RbSW62aY\pdoFtKEG|c3H5 NVfGU25COi53IN88US=> NVfYbWVsPCCmYYnz MnG0SG1UVw>? NFX6[mtKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2=
C6/36 MWnBcpRqfmm{YXygRZN{[Xl? M2i2UlIvPSEQvF2= M2nQcVQh\GG7cx?= MnrNSG1UVw>? NUPjVmpyUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCjc3nhckB1cWencjDtc5NyfWm2bzDDOk8{PiClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?=
U937 MlTHSpVv[3Srb36gRZN{[Xl? NYLQS4tpOSEQvF2= NHHYbVIyKGh? MUjEUXNQ NXL2TnVSWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO=
U937 Mn\KSpVv[3Srb36gRZN{[Xl? M3j3dFEh|ryP M37zflEhcA>? NIPobYFFVVOR MlP3VoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM>
murine mast cell NWHLcHpZTnWwY4Tpc44hSXO|YYm= M2fvN|Eh|ryP NHu4eY4zPCCq MlXVSG1UVw>? MU\Jcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>?
BV-173 M4K4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf1dYdYUUN3ME2wMlAxODByMEGwPUDPxE1?
K-562 MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfvU2tVUUN3ME2wMlAxODByMEK2OkDPxE1?
BL-70 MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r1WWlEPTB;MD6wNFAxODB6MkKg{txO
EM-2 Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vFVWlEPTB;MD6wNFAxODFyODFOwG0>
LAMA-84 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMECwNFA{OjFizszN
MEG-01 NF3rN5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrrTWM2OD1yLkCwNFAxQThizszN
EoL-1-cell NIjudlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17wOWlEPTB;MD6wNFAxOTNzIN88US=>
CTV-1 M{Xm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;tSXRKSzVyPUCuNFAxODRyNDFOwG0>
TE-15 M3\QO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMEC1PFkh|ryP
NOS-1 NU\pWVNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLxT4FjUUN3ME2wMlAxPjF|IN88US=>
D-336MG MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT2bIRUUUN3ME2wMlAxPjNizszN
LB1047-RCC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\uZVgxUUN3ME2wMlAxQTh7IN88US=>
LB996-RCC NWDVNI9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPoSWh1UUN3ME2wMlAxQTlzIN88US=>
SW982 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjySm9KSzVyPUCuNFEyOTVizszN
TK10 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XiW2lEPTB;MD6wNVE4PCEQvF2=
A704 M2fyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMEG0PVEh|ryP
TE-8 NHXFXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MortTWM2OD1yLkCxOVc3KM7:TR?=
DOHH-2 M3rrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMEG3NVkh|ryP
HOP-62 NHPaV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrUNINQUUN3ME2wMlAyQDN2IN88US=>
TE-12 MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zEV2lEPTB;MD6wNVg3OSEQvF2=
KGN Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMEG5OFIh|ryP
NCI-H1648 Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMEKwNVEh|ryP
OS-RC-2 M2LaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMEKwN{DPxE1?
GB-1 NF3LeFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\iTWM2OD1yLkCyNVU4KM7:TR?=
RXF393 M17nUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMEKzOVch|ryP
LC-2-ad M2SySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;xTWM2OD1yLkCyOVg3KM7:TR?=
KS-1 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMEK3N{DPxE1?
ETK-1 MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX0TWM2OD1yLkCyPFMzKM7:TR?=
SW954 M2qwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7TTWM2OD1yLkCyPVI4KM7:TR?=
Becker MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMEOwNFMh|ryP
MZ1-PC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nEfmlEPTB;MD6wN|EyQSEQvF2=
ES6 NFvnNnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi4c4tbUUN3ME2wMlA{OTl|IN88US=>
KURAMOCHI M1P4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfleJpIUUN3ME2wMlA{PDh5IN88US=>
CGTH-W-1 M32zTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMEO1OFgh|ryP
VA-ES-BJ MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPVNYxyUUN3ME2wMlA{QTB{IN88US=>
LXF-289 MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjnbYpFUUN3ME2wMlA{QTV4IN88US=>
MPP-89 M{fsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LlZmlEPTB;MD6wOFA1QSEQvF2=
SW872 NIXocXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XyVWlEPTB;MD6wOFE3OSEQvF2=
SNB75 NY\3SmlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn74TWM2OD1yLkC0OFM2KM7:TR?=
PSN1 NFfuWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXWO|BKSzVyPUCuNFQ1PzRizszN
LB831-BLC M4O0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7mZ4tKSzVyPUCuNFQ3ODlizszN
MFH-ino MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGKw[W5KSzVyPUCuNFQ4OjRizszN
TGBC24TKB NXLQOplzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\MOWlEPTB;MD6wOFc3OSEQvF2=
A388 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\0R5ZjUUN3ME2wMlA2ODl3IN88US=>
BB30-HNC MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr1[W5nUUN3ME2wMlA2PDN5IN88US=>
GI-ME-N MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfiZlJKSzVyPUCuNFYyOThizszN
TGBC1TKB MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEiyZm5KSzVyPUCuNFYyPjRizszN
TE-10 M2L6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonDTWM2OD1yLkC2N|U4KM7:TR?=
A498 NVn1PZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMEeyPFQh|ryP
TE-11 Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\6Wo9KSzVyPUCuNFc5PThizszN
BB65-RCC MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLk[3NRUUN3ME2wMlA5OjJ5IN88US=>
C2BBe1 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2niTWlEPTB;MD6wPFMxQCEQvF2=
NCI-H747 M1LN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HFNGlEPTB;MD6wPFM3OiEQvF2=
IST-MES1 NYLJPVVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDSVWFKSzVyPUCuNFg2PTJizszN
KALS-1 NV;VW4JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPheWtKSzVyPUCuNFk1QSEQvF2=
GCIY NHS5bWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMEm2OVYh|ryP
RL95-2 NGX0WFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXiTWM2OD1yLkGwN|gh|ryP
TE-1 Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3WxRmlEPTB;MD6xNFU1KM7:TR?=
NCI-H1355 M{jmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\mfXBKSzVyPUCuNVExOjhizszN
SW962 NUToeGpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXlTWM2OD1yLkGxNlkzKM7:TR?=
KLE NILyeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HTV2lEPTB;MD6xNVMyPyEQvF2=
MC116 MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjndXlKSzVyPUCuNVE1OSEQvF2=
NMC-G1 NW\NfZlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPORZJKSzVyPUCuNVE3ODZizszN
KU812 M2e4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMUG4PFMh|ryP
COLO-829 NVXIcI9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf4So1IUUN3ME2wMlEzOjF|IN88US=>
NTERA-S-cl-D1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMUKyPFMh|ryP
IST-MEL1 NX6wdol6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwMUO0OUDPxE1?
MLMA NE[1S3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PBN2lEPTB;MD6xOFA{OiEQvF2=
LS-123 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3CRVBWUUN3ME2wMlE1ODZ2IN88US=>
LB2518-MEL M2m0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfWUG52UUN3ME2wMlE1OTZ{IN88US=>
NB69 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHHbG9KSzVyPUCuNVQ1OzZizszN
8-MG-BA M{DhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2OzTGlEPTB;MD6xOVQ2QCEQvF2=
K5 NEXRXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPBTWM2OD1yLkG2OFg6KM7:TR?=
KINGS-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e0[2lEPTB;MD6xOlY3PiEQvF2=
SF268 MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMUe0NFQh|ryP
PF-382 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe4W3N7UUN3ME2wMlE4Pjd6IN88US=>
SH-4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DVSmlEPTB;MD6xPFQyOyEQvF2=
NALM-6 NVG3dnFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLrTWM2OD1yLkG5Nlk2KM7:TR?=
CP66-MEL M2HrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXGW29KSzVyPUCuNVk2OzFizszN
697 NGraZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHTV3ZKSzVyPUCuNVk6QDdizszN
CP67-MEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWC0TVhNUUN3ME2wMlIxPDh6IN88US=>
DSH1 NYXVSHZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfWW3lKSzVyPUCuNlQxODFizszN
HCE-4 Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PxSWlEPTB;MD6yOlQ{QSEQvF2=
MZ2-MEL Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDHe5BKSzVyPUCuNlg2OzdizszN
BL-41 M2XtRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\ISJZKSzVyPUCuNlkyOjNizszN
HUTU-80 NUTIWINOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwM{G0NkDPxE1?
LOXIMVI MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jWPWlEPTB;MD6zNVUxOyEQvF2=
no-10 NYXqVJVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof5TWM2OD1yLkOxPVMyKM7:TR?=
KARPAS-422 M3y5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfrWlY3UUN3ME2wMlM{QTl5IN88US=>
SW684 NVPZOnJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXRTWM2OD1yLkO0PVgh|ryP
SF126 NIGxUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwM{W0NUDPxE1?
D-263MG NV;OemJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnFOWh{UUN3ME2wMlM3OjJ2IN88US=>
OVCAR-4 NIGzRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LJfGlEPTB;MD6zO|Q{OyEQvF2=
BB49-HNC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTVSI8xUUN3ME2wMlM5PTl7IN88US=>
ONS-76 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\PUFdKSzVyPUCuOFI6PTFizszN
MZ7-mel NGXjdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrZTWM2OD1yLkS3PVEyKM7:TR?=
RCC10RGB MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwNEmxNUDPxE1?
BOKU MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnS0TWM2OD1yLkS5NVM{KM7:TR?=
no-11 NXPuVIp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfSU4xKSzVyPUCuOVAzOjhizszN
IST-SL2 M1nGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTVTWM2OD1yLkWwN|AzKM7:TR?=
RKO NFr5SlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PabWlEPTB;MD61Nlk3PiEQvF2=
HT-144 MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGzPIxPUUN3ME2wMlU{PjB7IN88US=>
NCI-H446 NGLyUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwNkK3OkDPxE1?
QIMR-WIL NHXXfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnCTWM2OD1yLkewOlI6KM7:TR?=
MHH-PREB-1 NGDSVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy1Tno1UUN3ME2wMlc1PDZ7IN88US=>
EW-16 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHmTWM2OD1yLke2NVc5KM7:TR?=
EW-24 NH7xOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;2fWlEPTB;MD63PFE3PSEQvF2=
LB373-MEL-D M1PWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwOEK1NFgh|ryP
TE-9 NImwbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwOEe1N|Ih|ryP
A3-KAW MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwOUi0OVIh|ryP
A101D M37Gfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzo[4NKSzVyPUGuNFMxPDNizszN
OCUB-M M2f6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwMES0NVIh|ryP
ES4 Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni0TWM2OD1zLkC1NVQ2KM7:TR?=
TE-6 MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwMkGyNlYh|ryP
D-502MG Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\ifWlEPTB;MT6yN|M4PiEQvF2=
KNS-42 NGTOTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LzVmlEPTB;MT6yOFQyOiEQvF2=
SNU-C2B NWXsUnpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;tU2lEPTB;MT6zNFU5QSEQvF2=
NCI-H1838 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFwM{C3N|Mh|ryP
NKM-1 NEPObo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXKXGVNUUN3ME2xMlMxQDV7IN88US=>
GI-1 NHvQcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfQfnJEUUN3ME2xMlM3OjJizszN
NB5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL6TWM2OD1zLkO5PFI4KM7:TR?=
CAS-1 NX;kPVJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLtTWM2OD1zLkSwPVkzKM7:TR?=
HCE-T MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTjZZNKSzVyPUGuOVY4OTRizszN
SBC-1 NHe5UHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmroTWM2OD1zLkW3PVg1KM7:TR?=
JiyoyeP-2003 M3rtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LMT2lEPTB;MT63N|Q3PiEQvF2=
TE-5 MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFwN{mxN|kh|ryP
CAN M2D3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vyWmlEPTB;MT64NlI2OiEQvF2=
SK-UT-1 NVfIVJdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJwMU[2PVMh|ryP
JVM-2 NGLVOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJwM{[yPFQh|ryP
LB771-HNC Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PvWWlEPTB;Mj61O|U2OSEQvF2=
NCCIT NWLZNXRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnSRVZiUUN3ME2yMlg3PjF4IN88US=>
NCI-H2126 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD1TWM2OD1{Lki3OVUzKM7:TR?=
Calu-6 MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO1PVJKSzVyPUOuNFU4PDFizszN
SK-LMS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrtSXVbUUN3ME2zMlEyQDh4IN88US=>
ARH-77 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fFT2lEPTB;Mz60OlkyPSEQvF2=
NB17 NH\nWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvWTWM2OD1|Lk[zPFQ4KM7:TR?=
A253 NYDIN|FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3OeWFoUUN3ME2zMlc{OjR4IN88US=>
OPM-2 MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTRwMke2PFUh|ryP
MV-4-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm1[I9uUUN3ME20MlM3PDV2IN88US=>
SR NEXKZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXHTJl7UUN3ME20MlQ6QTV2IN88US=>
KG-1 M17MWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;zToROUUN3ME20MlYxQDR3IN88US=>
OCI-AML2 NHm2TGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL0TWM2OD13Lki2NVU1KM7:TR?=
D-247MG M4nib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3Lc|JKUUN3ME22MlEzPTF7IN88US=>
DJM-1 NWHIZVUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf1TWM2OD14LkS4OVU5KM7:TR?=
RPMI-6666 M2nMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\tTWM2OD15LkK3NFY4KM7:TR?=
KARPAS-45 NYP1d|Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfVTWM2OD15LkWxOlcyKM7:TR?=
LP-1 NIm1Z4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3oTWM2OD15LkW0O|gzKM7:TR?=
RS4-11 NU\tXGFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zqdWlEPTB;Nz62OVc5PyEQvF2=
DU-4475 M33FU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;Dc25KSzVyPUiuNlE3PTJizszN
MONO-MAC-6 NVe0WJF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHPTWM2OD16LkK3NFY3KM7:TR?=
NCI-SNU-16 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLUTWM2OD16LkW2NVI5KM7:TR?=
SJSA-1 M3jIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\QXlhKSzVyPUiuO|I5ODVizszN
MMAC-SF MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnkUIV5UUN3ME24Mlc6OzB5IN88US=>
SK-NEP-1 NHnXS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfRTWM2OD16Lki5NVU2KM7:TR?=
J-RT3-T3-5 NXrKNpRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRThwOU[1Nlkh|ryP
SKM-1 M3\sOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HiR2lEPTB;OT6wNVc{PCEQvF2=
LB2241-RCC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TqUmlEPTB;OT6wNlAyOiEQvF2=
SIG-M5 NWLEelk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP4TWM2OD17LkCyOFk{KM7:TR?=
EVSA-T NIjIT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XSfGlEPTB;OT6yO|c6OyEQvF2=
GT3TKB MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTlwM{W1OFYh|ryP
NB6 NX;vfnk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPETWM2OD17LkmyNlU6KM7:TR?=
EHEB NFvMOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;MTGlEPTB;MUCuNFY2PiEQvF2=
HEL NYrFcJdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFyLkS3O|Yh|ryP
ALL-PO NUHGdol4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGj3TFZKSzVyPUGwMlc6OzhizszN
TGW MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTsb3FUUUN3ME2xNU4zQDJ6IN88US=>
BC-3 NH\aT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\VUo1sUUN3ME2xNk4yOTN6IN88US=>
IA-LM M1HqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\0W2lEPTB;MUKuOFQ1PSEQvF2=
UACC-257 NYnXbpZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTF{LkmxPVgh|ryP
KP-N-YS MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDFdYRIUUN3ME2xNk46Ojh|IN88US=>
Raji MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTZTWM2OD1zMz63OFk4KM7:TR?=
SF539 MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;NZmlEPTB;MUOuPFU2PyEQvF2=
DMS-153 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDrbpBKSzVyPUG0MlAxOjhizszN
L-540 Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT5UWc3UUN3ME2xOU4xPjd{IN88US=>
MN-60 M2fiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DXNmlEPTB;MUWuNVk4QSEQvF2=
RPMI-8866 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrLTWM2OD1zNz60OFU1KM7:TR?=
NCI-H510A NV25[mFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnDZ|lKSzVyPUG5MlM6PzNizszN
NB13 NXzNPXY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLyZ2tKSzVyPUG5MlQ5PzdizszN
HAL-01 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzFTWM2OD1zOT63OVQ{KM7:TR?=
NCI-H720 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\UNppKSzVyPUKwMlI4OzNizszN
REH MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJyLk[zOVch|ryP
KNS-81-FD M{nvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;FSodKSzVyPUKzMlE1PiEQvF2=
HC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rlWmlEPTB;MkSuOVU2OSEQvF2=
NCI-H2141 M2HXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\tTWM2OD1{ND63O|U1KM7:TR?=
MOLT-4 NH3V[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LxdWlEPTB;Mk[uOlc2OyEQvF2=
OMC-1 M{j1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL2ZZl1UUN3ME2yO{4yPDJ{IN88US=>
LC-1F NUHjR3dCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[5TWM2OD1{Nz6zNlQ2KM7:TR?=
NCI-H1304 NV;DWohkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[zcWVSUUN3ME2yPE4yPjJ6IN88US=>
BC-1 MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHtS2JKSzVyPUK4MlY2OSEQvF2=
NCI-H64 MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzhfnJsUUN3ME2yPU43OjV|IN88US=>
MOLT-16 M2\Ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXLSYRKSzVyPUK5MlYzQTJizszN
U-87-MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDYPHpKUUN3ME2zNE44PjZizszN
GAK Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfxTWM2OD1|MT6yOlg3KM7:TR?=
ES8 NV7UVmM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj2SG5OUUN3ME2zNk4yOjV{IN88US=>
HCC1599 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi3U2c1UUN3ME2zNk4{OzJ3IN88US=>
EB-3 NHfXcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fsPGlEPTB;M{SuN|EyPyEQvF2=
HCC1187 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH61XndKSzVyPUO1MlgxPTJizszN
SK-PN-DW MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTpTWM2OD1|Nj6xPVQ{KM7:TR?=
JVM-3 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;Ze2lEPTB;M{euNlM{QCEQvF2=
HCC2157 NU\ESph[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXkTWM2OD1|Nz65PVQ3KM7:TR?=
A4-Fuk NHrMepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTN6LkGwNFkh|ryP
COR-L279 M1KwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfmeIFDUUN3ME20NE4zQDVzIN88US=>
DEL MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLjTWM2OD12MT65NFg3KM7:TR?=
NCI-H1395 NUjUT5liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrrTWM2OD12Mj6wNVY{KM7:TR?=
MHH-NB-11 NGrKcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrPRlRKSzVyPUSzMlA5OThizszN
NCI-H2107 NGjrU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD1O|RQUUN3ME20N{41QDR4IN88US=>
NEC8 NWDZdIs5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13DemlEPTB;NESuN|M3KM7:TR?=
COLO-684 M3j2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHjTGFKSzVyPUS2MlIzPThizszN
LS-411N MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTkTWM2OD12OD60O|Q5KM7:TR?=

... Click to View More Cell Line Experimental Data

In vivo試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
臨床試験 Dasatinib has entered in a phase II clinical trial in the treatment of hemangiopericytoma and gastrointestinal stromal tumor.
特集

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ:

[1]

Kinase autophosphorylation assays Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.

細胞アッセイ:

[1]

細胞系 Ba/F3 cell lines
濃度 ~32 nM
処理時間 72 hours
方法

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.

動物実験:

[3]

動物モデル EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
製剤 DMSO
投薬量 30 mg/kg
管理 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Dasatinib SDF
分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管 2年-20℃
6月-80℃in solvent
別名 BMS-354825
溶解度 (25°C) * In vitro DMSO 98 mg/mL (200.81 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

カスタマーレビュー (10)


Click to enlarge
Rating
Source Cell Res, 2011, 21, 1080-1087. Dasatinib purchased from Selleck
Method Microangiography
Cell Lines embryos
Concentrations 30 μM
Incubation Time
Results MEK1/2 may cooperate with VEGFR to regulate blood vessel lumen diameter. We examined this hypothesis by combining VEGFR inhibitor Sunitinib and MEK1/2 inhibitor U0126. Indeed, U0126 (10 µM) combined with Sunitinib (20 µM) resulted in a reduction of vessel lumen size (Figure F), whereas individually they did not. Combined treatment of another MAP kinase signaling pathway inhibitor Dasatinib (20 µM) with Sunitinib (20 µM) produced a similar phenotype as PP1, whereas each individual inhibitor did not result in any vessel shrinkage even at much higher concentrations ( Figure C).Since there are three major VEGF receptors, it is desirable to determine which receptor is involved in combinatory action with MEK1/2. To address this issue, additional highly selective VEGFR inhibitors PTK787 and ZM323881 were tested. Both of these inhibitors (PTK787 or ZM323881), when individually combined with Dasatinib or U0126, induced a reduction of vessel lumen size (Figure D, E, G, and H).

Click to enlarge
Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib purchased from Selleck
Method Assessment of cell viability and apoptosis
Cell Lines B-CLL patient leukemic cells
Concentrations 2-10 μM
Incubation Time 48 h
Results The Dasatinib+Nutlin-3 combination promotes synergistic cytotoxicity in primary CLL cells as well as in p53 wild-type and p53 deleted/ mutated leukemic cell lines.

Click to enlarge
Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib purchased from Selleck
Method Western blot
Cell Lines Leukemic cell lines
Concentrations 10 μM
Incubation Time 24 h
Results Dasatinib marginally affected both the basal levels of p53 and the accumulation of p53 induced by Nutlin-3 in the p53 wild -type cells (Fig. A).Interestingly, however, levels of both MDM2 and p21 proteins, 2 of the best characterized transcriptional targets of p53, weres significantly (P < 0.05) decreased in cells treated with Dasatinib+ Nutlin-3 with respect to cells treated with Nutlin-3 alone (Fig. B).

Click to enlarge
Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib purchased from Selleck
Method Phospho-kinase array analysis
Cell Lines EHEB cell lines/BJAB cell lines
Concentrations 10 μM
Incubation Time 16 h
Results Although Nutlin-3 had no effects on these pathways, Dasatinib alone as well as Dasatinib+Nutlin-3 markedly inhibited the basal phosphorylation of ERK1/2, p38/MAPK, and Akt . Of interest, the combination of Dasatinib+Nutlin-3 selectively enhanced (P < 0.05) the inhibition of Akt phosphorylation with respect to Dasatinib alone, as validated by Western blot analysis.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 1457-1466. Dasatinib purchased from Selleck
Method MTT assay
Cell Lines MOLM-13 cells, HL-60 cells
Concentrations 1-15 μM
Incubation Time 24-72 h
Results Dasatinib and other TKI decreased the viability of the two myeloid cell lines in a dose- and time-dependent manner. Nevertheless, the anti-leukemic efficacy of Dasatinib and other TKI varied considerably in both cell lines.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 1457-1466. Dasatinib purchased from Selleck
Method Evaluation of differentiation
Cell Lines MOLM-13 cells, HL-60 cells
Concentrations 5 μM
Incubation Time
Results In a first series of experiments, we assessed four signs of morphological differentiation, May-Gruenwald-Giemsa staining of MOLM-13 cells demonstrated that dasatinib induced a dose-dependent decrease in cytoplasmic basophilia and in the nucleo-cytoplasmic ratio. Dasatinib also led to the appearance of dented nuclei and cytoplasmic granulation( Fig.A and B).In HL-60 cells,dasatinib(5 μM) once more exhibited the highest differentiation-inducing capacity. Thus dasatinib diminished basophilia of the cytoplasm concomitantly with the nucleo-cytoplasmic ratio, and induced the appearance of nuclear lobulation and cytoplasmic granules(Fig. G). Next, we determined the degree of CD11b expression, a marker indicating myeloid differentiation, in TKI-treated MOLM-13 dasatinib exhibited the most pronounced capacity to increase CD11b surface expression( Fig. C and D).To corroborate the TKI-driven differentiation, we quantified the enzymatic activity of alkaline phosphatase by means of the NBT-reduction assay after an incubation period of 6 days in MOLM-13 cells.,Once again, the NBT-reductive activity was highest in cells treated with dasatinib, which was as active as the positive control, ATRA( Fig. E and F)

Click to enlarge
Rating
Source Invest New Drugs , 2010, 30, 417-422. Dasatinib purchased from Selleck
Method Assessment of cell viability
Cell Lines leukemic cells
Concentrations 10 μM
Incubation Time 24/48 h
Results Dasatinib dose-dependently reduced cell viability in all leukemic cell lines, with variable efficacy irrespect ively of the p53 status. In particular, when used at 10 μM, Dasatinib induced a progressive decrease of the total number of viable cells ranging from approximately 30% (JVM-2 and MEC-2) to 50% (EHEB and BJAB) after 48 h of treat ment (Fig.a). In order to investigate whet her the decreased leukemic cell viability was mainly due to either cytotoxic or cytostatic activity, we have analyzed the effects of Dasatinib on apoptosis,As shown in Fig. b, exposure to Dasatinib induced a significant (p < 0.05) increase of apoptosis in all leukemic cell lines, as evaluated by Annexin-V/PI staining at 48 h of treatment.

Click to enlarge
Rating
Source Invest New Drugs , 2010, 30, 417-422. Dasatinib purchased from Selleck
Method phospho-kinase array analysis
Cell Lines EHEB (p53wt) cell lines, BJAB (p53mut) B cell lines
Concentrations
Incubation Time 24 h
Results As shown in Fig. a , the most evident effects of Dasatinib in both cell models were represented by a significant down-regulation of the phosphorylation levels of p38 MAPK, ERK1/2 and CREB. In addition, densitometric analysis of the phospho-kinase array demonstrated that Dasatinib also inhibited the phosphorylation levels of several STAT family members (STAT1, STAT2, STAT3, STAT5a/b and STAT6), the most evident effect in both p53 wild-type (EHEB) and p53 mutated (BJAB) cell lines being on STAT2, STAT3 and STAT6 (Fig. b)

Click to enlarge
Rating
Source Invest New Drugs , 2010, 30, 417-422. Dasatinib purchased from Selleck
Method Western blot
Cell Lines p53wild-type(EHEB, JVM-2) cell lines, p53mutated(MEC-2, BJAB) cell lines
Concentrations 10 μM
Incubation Time 24 h
Results "Upon exposure to Dasatinib, a decrease of phosphorylated proteins was confirmed by Western blot analys is in all cell lines investigated without significant differences between p53wild-type and p53mutated cell lines.

Click to enlarge
Rating
Source Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck
Method Cell vability assays
Cell Lines A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2, HepG2 cell lines
Concentrations 0.001-1000 nM
Incubation Time 24/96 h
Results

製品表彰状 (57)

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related Src 阻害剤

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2nM and 6 nM, respectively.

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • BAY 87-2243

    BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib(AZD0530)は、c-SrcのためのSrc阻害剤で、IC50 が2.7 nMです。

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Bosutinib (SKI-606)

    Bosutinib(SKI-606)はそれぞれ1.2nMと1nMのIC50値による新しい二重Sarcoma/アベルソン(Src/Abl)チロシン・キナーゼ阻害剤です。

  • KX2-391

    KX2-391は、Srcのサブストレート結合部位を目標とする非常に選択的な非ATP Srcキナーゼ阻害剤で、Srcの高水準を表すガン細胞線で、非常に強い反増殖的な活性を示します。

  • PP1

    PP1は、Lck/Fynのための強力で選択的なSrc阻害剤で、IC50 が 5 nM/ 6 nMです。

  • PP2

    PP2は、Src キナーゼ阻害剤で、GST-Src活動を強力に禁止します。

最近見られたアイテム

Tags: Dasatinibを買う | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
お問い合わせ